RB 240
Alternative Names: RB-240Latest Information Update: 28 Dec 2022
At a glance
- Originator Refuge Biotechnologies
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diffuse large B cell lymphoma
Most Recent Events
- 28 Dec 2022 Preclinical trials in Diffuse large B cell lymphoma in USA (Parenteral) before December 2022 (Refuge Biotechnologies pipeline, December 2022)